Show
Sort by
-
- Journal Article
- A1
- open access
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
-
- Journal Article
- A1
- open access
Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
-
- Journal Article
- A1
- open access
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force
-
Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America : a comparative study with the general population and data from the ASAS-COMOSPA study
-
Inequity in biological DMARD prescription for spondyloarthritis across the globe : results from the ASAS-COMOSPA study
-
Work participation in spondyloarthritis across countries : analysis from the ASAS-COMOSPA study
-
Measurement properties of the ASAS Health Index : results of a global study in patients with axial and peripheral spondyloarthritis
-
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V) : 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
-
Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis : 104-week results from a randomized, placebo-controlled study
-
- Journal Article
- A1
- open access
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis : 4-year outcomes from RAPID-axSpA